- Home
- GH vs OKLO Comparison
GH vs OKLO Comparison
Compare GH & OKLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- OKLO
- Stock Information
- Founded
- GH 2011
- OKLO 2013
- Country
- GH United States
- OKLO United States
- Employees
- GH N/A
- OKLO N/A
- Industry
- GH Medical Specialities
- OKLO
- Sector
- GH Health Care
- OKLO
- Exchange
- GH Nasdaq
- OKLO NYSE
- Market Cap
- GH 4.7B
- OKLO 4.0B
- IPO Year
- GH 2018
- OKLO N/A
- Fundamental
- Price
- GH $45.13
- OKLO $31.32
- Analyst Decision
- GH Strong Buy
- OKLO Buy
- Analyst Count
- GH 14
- OKLO 3
- Target Price
- GH $39.93
- OKLO $22.33
- AVG Volume (30 Days)
- GH 1.9M
- OKLO 15.2M
- Earning Date
- GH 02-20-2025
- OKLO 02-13-2025
- Dividend Yield
- GH N/A
- OKLO N/A
- EPS Growth
- GH N/A
- OKLO N/A
- EPS
- GH N/A
- OKLO N/A
- Revenue
- GH $692,256,000.00
- OKLO N/A
- Revenue This Year
- GH $32.21
- OKLO N/A
- Revenue Next Year
- GH $16.90
- OKLO N/A
- P/E Ratio
- GH N/A
- OKLO N/A
- Revenue Growth
- GH 29.20
- OKLO N/A
- 52 Week Low
- GH $15.81
- OKLO $5.35
- 52 Week High
- GH $45.66
- OKLO $31.91
- Technical
- Relative Strength Index (RSI)
- GH 79.68
- OKLO 66.48
- Support Level
- GH $36.45
- OKLO $23.09
- Resistance Level
- GH $39.29
- OKLO $26.49
- Average True Range (ATR)
- GH 2.35
- OKLO 3.22
- MACD
- GH 0.75
- OKLO 0.30
- Stochastic Oscillator
- GH 96.63
- OKLO 94.92
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About OKLO OKLO INC
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.